---
layout: default
title: Rocuronium
parent: Model Prediction Only (L5)
nav_order: 813
evidence_level: L5
indication_count: 10
---

# Rocuronium
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Rocuronium: From Neuromuscular Blockade in Anesthesia to Migraine Disorder

## One-Sentence Summary

Rocuronium is an injectable non-depolarizing neuromuscular blocker used as an anesthesia adjunct. The TxGNN model predicts it may be effective for **migraine disorder**, but this is a graph-based prediction only. Only **1 clinical trial** is linked to it, a pediatric pharmacokinetics study with no migraine endpoint, and there are **no publications**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the Canadian licence records; known use is neuromuscular blockade during anesthesia |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 6 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Rocuronium is known to be a non-depolarizing neuromuscular blocker. It antagonizes nicotinic acetylcholine receptors at the motor end plate and paralyzes skeletal muscle for intubation and surgery.

The review found **no plausible mechanistic link** between this action and migraine. Migraine involves mechanisms such as cortical spreading depression and trigeminovascular activation, which neuromuscular blockade does not address. The same applies to the second-ranked prediction, migraine with brainstem aura. The high TxGNN score most likely reflects proximity in the knowledge graph, such as shared neighbors among migraine-related disease nodes, rather than a pharmacological rationale.

In short, the prediction should be treated as a computational signal, not as evidence of efficacy.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3,520 | Pharmacokinetics of understudied drugs given to children as standard of care. It does not test migraine efficacy (relevance grade C). |

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Six licences are recorded; five are shown below.

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2528657 | Rocuronium Bromide Injection | Injection | Not listed in the record |
| 2517744 | Rocuronium Bromide Injection | Injection | Not listed in the record |
| 2469774 | Rocuronium Bromide Injection | Injection | Not listed in the record |
| 2529831 | Rocuronium Bromide Injection | Injection | Not listed in the record |
| 2498820 | Rocuronium Bromide Injection | Injection | Not listed in the record |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on model output alone (L5), with no mechanistic rationale and no migraine-specific trials or publications. Rocuronium is also an injectable agent used only during anesthesia, which makes chronic use for migraine impractical.

The other top predictions fare no better. Eight of the ten lack any drug-specific evidence. The rank 10 prediction, headache disorder (L4), has only perioperative records in which headache appears as an adverse event or outcome, for example after electroconvulsive therapy (ECT). One paper compares a rocuronium-sugammadex regimen with succinylcholine for post-ECT myalgia and headache. That reflects avoiding succinylcholine-related effects, not a headache-treating action of rocuronium.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications, which block the safety screening step
- Mechanism of action data, for example from DrugBank
- Approved indication text and dosage form details for each DIN
- Any drug-specific preclinical or clinical evidence in migraine, which currently does not exist in the retrieved data
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

